Importantly, CXCR3 is highly expressed by T-cells associated with chronic inflammation and/or autoimmune conditions such as RA, Ulcerative Colitis, Lupus or organ transplant rejection and CXCR3 inhibitors have been shown to be beneficial in preclinical disease models of these pathological conditions [7, 8]. The gene discussed is CXCR3; the disease is systemic lupus erythematosus.